Bernstein Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of $221

Benzinga Newsdesk www.benzinga.com Positive 77.7%

Neg 0% Neu 0% Pos 77.7%

Bernstein analyst Jeffrey Walch initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform rating and announces Price Target of $221.